Since TACE is a local treatment of liver cancer, the administration of MDR1 and ABCG2 inhibitors via TACE is expected to enhance the efficacy of DOX to kill HCC while minimally affect the systemic exposure of DOX. The gene discussed is ABCG2; the disease is hepatocellular carcinoma.